While BRAF V600E was selected as a proof-of-concept marker because of its established role in papillary thyroid carcinoma, the broader implication lies in showing that CytoMatrix may serve as a platform for routine molecular testing within standard cytopathology practice [25,34]. The gene discussed is BRAF; the disease is differentiated thyroid carcinoma.